BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026
BridgeBio Pharma announced it will share a late-breaking oral presentation of randomized controlled trial data on oral infigratinib in achondroplasia from the PROPEL 3 study at the ESPE Annual Meeting 2026 in Marseille, France, September 8-10, 2026. The presentation by Julie Hoover-Fong of Johns Hopkins University is scheduled for September 9, alongside two posters and one ePoster covering longer-term infigratinib data, the ongoing Phase 2/2b PROPEL I&T study in children under 3, and qualitative research on hypochondroplasia.
Key figures
- Drug Name
- oral infigratinib
- Phase Of Trial
- Phase 2/2b (PROPEL I&T); PROPEL 3 described as a randomized controlled trial
- Conference
- ESPE Annual Meeting 2026, Marseille, France
- Presentation date
- September 9, 2026
- Presentations count
- 1 late-breaking oral, 2 posters, 1 ePoster
- Achondroplasia prevalence us eu
- approximately 55,000
- Patients with open growth plates
- up to 10,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.